Glenmark Pharmaceuticals has informed that in furtherance to the notice issued by the Company on May 31, 2016 announcing the launch of the FCCBs, the Company has entered into a Subscription Agreement dated May 31, 2016 with J.P. Morgan Securities plc (the book running lead manager to the Issue). In terms of the Subscription Agreement, the Company will issue the FCCBs at 100% of their principal amount on or about June 28, 2016 (Closing Date).
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1677.10 |
| Dr. Reddys Lab | 1238.10 |
| Cipla | 1238.70 |
| Zydus Lifesciences | 942.95 |
| Lupin | 2327.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: